Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy
  • Get the full experience

    We save the real magic for signed-in users.

Logo
603127 CG​

Joinn Laboratories(China)Co.,Ltd. Class A(603127 CG)

$45.35-0.200.44%(Market Closed · 07:00:00 UTC · (15 min delay))

Overview

Profile

Financials & Metrics

FinancialsChartingEmployees

Joinn Laboratories(China)Co.,Ltd. Class A — Company Profile

Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.

Sector
Health Care
Industry
Health Care Equipment & Supplies
Exchange
CG
CEO
Daniel Gao
Headquarters
Beijing, BE, CN
IPO Date
Aug 25, 2017
Employees
2,500
Website
www.joinnlabs.com

Key Metrics

Price
$49.30
Market Cap
$36.94B
Revenue (TTM)
$316.14M
Net Income (TTM)
$238.36M
EPS (TTM)
0.32
P/E (TTM)
74.62
P/B (TTM)
4.32
Dividend Yield
9.31%
ROE (TTM)
2.79%
ROA (TTM)
2.37%
Operating Margin
80.95%
Beta
0.10

Dividends

Last Dividend
$0.03
Last Yield
0.09%

Summary

Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.

Website
www.joinnlabs.com
Location
Beijing, BE, CN
Phone86 10 6786 9966
Employees2,500
CEODaniel Gao
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO DateAug 25, 2017

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Key Stats

Trading

Px/Chg 1D$49.30 / +10.00%
Avg Volume27.71M
Beta0.10
Mkt Cap36.94B
FD Mkt Cap34.82B

Float

Shrs Out/Float749.35M / 490.90M
Short Float0.00%
Days to Cover0.00
Stock Repurchased$0.00

Current Valuation

EV35.97B
EV/EBITDA66.15
EV/Sales21.33
P/B4.32
P/S21.91
FCF Yield-0.65%
ROE2.79%
ROA2.37%
Current Ratio4.02

Dividend

Cash$0.03
Yield9.31%
Yield (TTM)9.31%

Estimates

P/E74.62
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgMar '23Mar '24Mar '25Mar '26Sep '26
PRICE-BASED RATIOS
Price / Earnings107.6326.5934.11212.40110.08154.99
Price / Sales35.7012.605.707.8035.53116.86
Price / Book Value2.853.491.641.952.874.32
Price / Free Cash Flow59.8941.0331.48226.26153.52-152.86
ENTERPRISE VALUE METRICS
Enterprise Value22,052.225,743.610,723.414,829.822,991.735,972.6
Enterprise Value / Sales34.2411.354.517.3534.18113.79
Enterprise Value / EBITDA70.5332.0815.8582.5881.82140.34
Enterprise Value / EBIT93.8236.3418.71177.1996.52140.34

Financials

Full Financials
Millions CNY5Yr CAGR (%)Dec '21Dec '22Dec '23Dec '24Dec '25
INCOME STATEMENT
Revenue2.2%1,516.72,268.02,376.52,018.31,657.6
Gross Income-17.4%737.81,081.4981.6520.8343.3
EBITDA-36%490.3802.6676.5179.6483.2
EBIT-5%415.8708.4573.283.7338.9
Net Income-14.5%557.51,074.3397.074.1297.8
EPS (Diluted)-15.1%0.771.430.530.100.40
BALANCE SHEET
Cash & ST Inv-8.3%4,835.13,325.33,236.32,361.33,421.7
Total Assets3.2%8,537.110,364.210,027.29,396.29,681.9
Total Liabilities-65.4%1,392.62,173.31,746.11,317.01,356.6
Total Shareholder Equity3.9%7,136.28,183.78,279.38,078.88,325.0
CASH FLOW
Net Operating Cash Flow-10.3%685.7971.1647.7338.9444.6
Cap Ex-11.8%-237.2-274.8-192.7-269.4-143.6
Free Cash Flow-9.5%448.4696.2430.269.5301.0

Enterprise Value Bridge

Millions CNY23 Oct '26
Price (As of 23 Oct '26)44.17
Basic Shares749.35
Market Cap33,098.7
Diluted Shares744.86
Fully Diluted Shares Outstanding744.86
Fully Diluted Market Cap32,900.7
+Consolidated Debt12.5
−In-the-Money Convertible Debt—
+Capital Leases12.5
+Operating Leases—
−Cash & Equivalents-983.1
−Short-term Investments-1,510.9
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest0.4
+Pension Liabilities—
Enterprise Value32,128.5

Related companies

WuXi AppTec Co., Ltd.

WUXAY US

Natera, Inc.

NTRA US

Labcorp Holdings Inc.

LH US

Guardant Health, Inc.

GH US

WuXi XDC Cayman Inc

2268 HK

Caris Life Sciences, Inc.

CAI US

Sonic Healthcare Ltd / ADR

SKHHY US

GRAIL, Inc.

GRAL US

RadNet, Inc.

RDNT US

Sotera Health Co

SHC US

Vontier Corp

VNT US

DiaSorin S.p.A.

DSRLF US